NASDAQ:OCGN - Nasdaq - US67577C1053 - Common Stock - Currency: USD
Overall OCGN gets a fundamental rating of 2 out of 10. We evaluated OCGN against 563 industry peers in the Biotechnology industry. Both the profitability and financial health of OCGN have multiple concerns. OCGN is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.03% | ||
ROE | -222.66% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.92 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.44 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.86 | ||
Quick Ratio | 2.86 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.7152
-0.04 (-5.89%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 41.2 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7.05 | ||
P/tB | 7.05 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -80.03% | ||
ROE | -222.66% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.92 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 172% | ||
Cap/Sales | 66.78% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.86 | ||
Quick Ratio | 2.86 | ||
Altman-Z | -5.44 |